TACR1 and migraine disorder: Contrasting actions of SP and α-CGRP can also be seen in migraine therapy: even though both peptides promote the typical neurogenic inflammation, blockade of SP signaling through application of NK1R antagonists has no effect on acute migraine [46], whereas blockade of α-CGRP or its receptor has a strong potential for acute and preventive treatment of migraine-related pain [47].